Objective: This study aims to describe and compare the transplant outcomes of kidney transplant patients who received either mycophenolate mofetil or enteric-coated mycophenolate sodium with the concomitant use of proton pump inhibitors. Methods: This was a 9-year retrospective observational study conducted between January 1, 2011, and December 31, 2019 at Ibni Sina Hospital, Nephrology Department, Ankara University Faculty of Medicine. Results: Among 349 kidney transplant patients, 290 were eligible for the study aged [median (interquartile range)] 41 (33-50) years in the mycophenolate mofetil group and 41 (31-50) years in the enteric-coated mycophenolate sodium group. More than half of them were male (54% in mycophenolate mofetil vs. 60% in enteric-coated mycophenolate sodium groups) and the majority received a living transplant (79% in both). There was no statistically significant difference in transplant outcomes including protein/creatinine ratio [(median (interquartile range)): 150 (2-308) vs. 153 (58-397), P = .742], creatinine doubling (8% vs. 10%, P = .589), change in medications (46% vs. 48%, P = .775), delayed graft function (8% vs. 14%, P = .153), biopsy-proven acute rejection (14% vs. 18%, P = .327), graft loss (7% vs. 10%, P = .351), and overall mortality (4% vs. 6%, P = .337) among the patient groups who received either mycophenolate mofetil or enteric-coated mycophenolate sodium, respectively. Conclusion: The transplant outcomes including graft survival, biopsy-proven acute rejection, graft loss, or delayed graft function of the kidney transplant patients who received mycophenolate mofetil or enteric-coated mycophenolate sodium with proton pump inhibitors were similar. Therefore, proton pump inhibitors and mycophenolate mofetil or enteric-coated mycophenolate sodium can be prescribed together safely with appropriate follow-up intervals.